Skip to main content

Advertisement

SpringerLink
Log in

Recognizing the toxicity of “Nontoxic” drugs employed in the management of malignant disease

  • Editor’s Commentary
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Burton A: Is it all over for erythropoietin? Lancet Oncol 2007, 8:285.

    Article  PubMed  Google Scholar 

  2. Henke M, Laszig R, Rube C, et al.: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 2003, 362:1255–1260.

    Article  PubMed  CAS  Google Scholar 

  3. Wright JR, Ung YC, Julian JA, et al.: Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small cell lung cancer with disease-related anemia. J Clin Oncol 2007, 25:1027–1032.

    Article  PubMed  CAS  Google Scholar 

  4. Yang Y-X, Lewis JD, Epstein S, et al.: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006, 296:2947–2953.

    Article  PubMed  CAS  Google Scholar 

  5. Hassett MJ, O’Malley J, Pakes JR, et al.: Frequency and cost of chemotherapy-related serous adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006, 98:1108–1117.

    Article  PubMed  Google Scholar 

  6. Tolba KA, Deliargyris EN: Cardiotoxicity of cancer therapy. Cancer Invest 1999, 17:408–422.

    Article  PubMed  CAS  Google Scholar 

  7. Reimer RR, Hoover R, Fraumeni JF, et al.: Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med 1977, 297:177–181.

    Article  PubMed  CAS  Google Scholar 

  8. van Leeuwen FE, Benraadt J, Coebergh JWW, et al.: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994, 343:448–452.

    Article  PubMed  Google Scholar 

  9. Mortensen M, Lawson W, Montazem A: Osteonecrosis of the jaw associated with bisphosphonate use: Presentation of cases and literature review. Laryngoscope 2007, 117:30–34.

    Article  PubMed  CAS  Google Scholar 

  10. Bohlius J, Wilson J, Seidenfeld J, et al.: Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006, 98:708–714.

    Article  PubMed  CAS  Google Scholar 

  11. Glaspy JA: Cancer patient survival and erythropoietin. JNCCN 2005, 3:796–804.

    PubMed  Google Scholar 

  12. Phrommintikul A, Haas SJ, Elsik M, et al.: Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007, 369:381–388.

    Article  PubMed  CAS  Google Scholar 

  13. Han ES, Monk BJ: What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 2007, 105:3–6.

    Article  PubMed  CAS  Google Scholar 

  14. Tejpar S, Piessevaux H, Claes K, et al.: Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 2007, 8:387–394.

    Article  PubMed  CAS  Google Scholar 

  15. Rini BI, Tamaskar I, Shaheen P, et al.: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007, 99:81–83.

    Article  PubMed  CAS  Google Scholar 

  16. Guarneri V, Lenihan DJ, Valero V, et al.: Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer Center experience. J Clin Oncol 2006, 24:4107–4015.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Texas M.D. Anderson Cancer Center, Mail Box 121, 1515 Holcombe Boulevard, Houston, TX, 77030, USA

    Maurie Markman MD

Authors
  1. Maurie Markman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maurie Markman MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Markman, M. Recognizing the toxicity of “Nontoxic” drugs employed in the management of malignant disease. Curr Oncol Rep 9, 329–330 (2007). https://doi.org/10.1007/s11912-007-0041-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-007-0041-0

Search

Navigation